CUE Company Profile and Key Details

Q: Who are the executives of CUE?

Dr. Ronald D. Seidel III, Ph.D.Co-FounderDr. Anish Suri Ph.D.Pres & Chief Scientific OfficerDr. Matteo Levisetti M.D.Chief Medical OfficerMr. Daniel R. Passeri J.D., M.Sc., MSc.Chief Executive Officer & DirectorMs. Kerri-Ann MillarChief Financial OfficerGeorge B. Zavoico Ph.D.Vice President of Investor Relations & Corporation Devel.Mr. Colin G. Sandercock J.D., MSESenior Vice President, Gen. Counsel & Sec.Dr. Kenneth J. Pienta M.D.Acting Chief Medical OfficerDr. Steven C. AlmoCo-Founder and Chairman of Scientific & Clinical Advisory BoardDr. Rodolfo J. ChaparroCo-Founder & Senior AdvisorMs. Patricia NasshornChief Bus. Officer

NASDAQ : CUE

Cue Biopharma

$0.36

-0.0324-8.25%

At Close 4:00 PM

$0.38

+0.0165+4.58%

After-Market 08:30 PM

67.17

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Cue Biopharma, Inc. (CUE) stock declined over -8.25%, trading at $0.36 on NASDAQ, down from the previous close of $0.39. The stock opened at $0.39, fluctuating between $0.34 and $0.40 in the recent session.

Stock Snapshot

0.3929

Prev. Close

28.42M

Market Cap

0.34

Day Low

-0.88

P/E Ratio

-0.41

EPS (TTM)

-0.85

Cash Flow per Share

0.39

Open

78.84M

Number of Shares

0.3998

Day High

99.65%

Free Float in %

0.79

Book Value

979.28K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jan 09, 2026	0.39	0.40	0.34	0.36	877K
Jan 08, 2026	0.40	0.41	0.37	0.39	531.46K
Jan 07, 2026	0.37	0.41	0.37	0.39	819.71K
Jan 06, 2026	0.38	0.41	0.35	0.37	969.43K
Jan 05, 2026	0.36	0.44	0.34	0.38	3.7M
Jan 02, 2026	0.31	0.34	0.30	0.34	3.38M
Dec 31, 2025	0.30	0.32	0.29	0.31	769.81K
Dec 30, 2025	0.26	0.32	0.26	0.30	2.04M
Dec 29, 2025	0.32	0.32	0.26	0.28	3.06M
Dec 26, 2025	0.24	0.33	0.24	0.32	6.98M
Dec 24, 2025	0.25	0.25	0.23	0.24	725.05K
Dec 23, 2025	0.26	0.26	0.24	0.24	867.51K
Dec 22, 2025	0.27	0.27	0.24	0.25	1.91M
Dec 19, 2025	0.26	0.31	0.24	0.27	5.22M
Dec 17, 2025	0.40	0.42	0.40	0.40	214.28K
Dec 16, 2025	0.46	0.47	0.41	0.41	348.03K
Dec 15, 2025	0.49	0.50	0.46	0.46	245.49K
Dec 12, 2025	0.49	0.51	0.47	0.49	395.99K
Dec 11, 2025	0.50	0.51	0.48	0.49	437.44K
Dec 10, 2025	0.49	0.51	0.48	0.48	244.19K

Contact Details

Boston, MA 02139

United States

https://www.cuebiopharma.com 617 949 2680

About Company

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Stock Peers

REGN

-4.46-0.56%

Regeneron Pharmaceuticals, Inc.$796.55 ARGX

-7.07997-0.89%

argenx SE$788.49 MDGL

-42.16-7.58%

Madrigal Pharmaceuticals, Inc.$514.06 UTHR

-7.6-1.55%

United Therapeutics Corporation$483.23 VRTX

-5.82-1.24%

Vertex Pharmaceuticals Incorporated$463.86 ALNY

-1.11-0.28%

Alnylam Pharmaceuticals, Inc.$398.29 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

-5.93-2.01%

Praxis Precision Medicines, Inc.$288.45 KRYS

12.5+5.02%

Krystal Biotech, Inc.$261.41 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Company Overview

Cue Biopharma, Inc. (NASDAQ:CUE) closed at $0.36 USD, losing -$0.03 (-8.25%) from the previous close of $0.39. The stock is currently mid-range between its 52-week high and low $0.23 and $1.54. With a market capitalization of about $28.42 million, Cue Biopharma, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.47). Key stats such as the average daily volume over the past year has been around 832.47 thousand shares, in line with its 52-week average. Headquartered in Boston, MA, Cue Biopharma, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Usman Azam, the company employs approximately 41 people and listed since January 02, 2018. Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders.

Technical Performance

CUE has shown mixed momentum, gaining 28.65% over the past week and -47.78% over the past quarter, though year-to-date performance is up 28.65%. Short-term trend indicators are bullishly aligned (SMA20 2.44%, SMA50 -29.92%, SMA200 -48.28%). The stock’s 14-day RSI is 43.44 (neutral), while the ATR of 0.05 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -76.59% below its high and over 56.6% above its low. Average 10-day trading volume of 1.71 million shares is significantly above the 3-month average of 754.09 thousand, indicating heightened recent market interest.

Valuation Metrics

Cue Biopharma, Inc. trades at a P/E ratio of -0.88, slightly below the S&P 500 average, with a price-to-sales ratio of 3.43 and a price-to-book ratio of 1.9 suggesting the stock is closer to book value. The P/FCF stands at -1.0, also above market averages.

Dividend & Fair Value

Cue Biopharma, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.76. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Cue Biopharma, Inc. generated EPS of -$0.46 over the past year. Five-year average earnings growth is 15.39%. Wall Street analysts project EPS growth of 14.19% annually over the next five years. The latest quarter delivered EPS of -$0.07. The next quarter is forecast at -$0.10. Next year's EPS is expected at $1.77. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $4.00 to $2.00. The high target offers 1011.11% upside. The low target suggests 455.56% downside. The mean target is $3.00. This offers 733.33% upside. Cue Biopharma, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended November 12, 2025, missed forecasts by -36.36%. The prior quarter beat by -30.77%. Over the last six quarters, Apple has recorded several small beats. These include -31.03% in August 14, 2024.

Shareholding & Insider Activity

Cue Biopharma, Inc. has 76.85 million shares outstanding. The public float is 76.58 million shares, elevated short interest at 1.17% of float. This equals 898.16 thousand shares. The short ratio is 7.02 days. Institutional investors hold 22.7% of the float. Insiders own 0.35%. Fletcher Aaron G.L. holds 885.00 thousand shares, Gray Cameron has 677.50 thousand shares and PASSERI DANIEL R has 164.58 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Cue Biopharma generated $5.49M in revenue, or $0.12 per share. Gross margin was 37.41%, operating margin -947.03%, and net profit margin -924.10%. Returns are negative, with ROA at -82.45% and ROE at -136.80%.
On valuation metrics, Cue Biopharma trades at a P/E of -0.88, P/S of 3.43 and P/B of 1.90. The current ratio is 1.60 and quick ratio is 1.60. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -13215.12 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.42, supported by a cash flow-to-debt ratio of -3.69.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Cue Biopharma posted revenue of $5.49M, down slightly from $1.25M in the prior quarter. Gross profit was $2.05M (margin 37.41%). Operating income was - $51.99M (margin -947.0%). Net income was- $50.73M (EPS - $1.11).
The company ended the quarter with $48.51M in cash and short-term investments, a total debt of $14.70M, and net debt of - $33.82M. Total assets were $61.53M, with equity of $37.09M. Financials further reflected weakness, with operating cash flow of - $39.96M, free cash flow of - $39.96M, and capital expenditures of $0.00.

Price Forecast & Outlook

Our AI price prediction model suggests that Cue Biopharma, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -25.1%, with price expected at $0.27 by January 23, 2026, within a range of $0.19 to $0.35 3-Month Outlook: Projected fall of -8.46%, reaching $0.33 by April 09, 2026, with a range of $0.20 to $0.37. 1-Year Outlook: Projected gain of 210.68%, with price at $1.12 by December 31, 2026, within a range of $0.00 to $1.36.

Key Takeaways

Cue Biopharma, Inc. (NASDAQ:CUE) shares are up 28.65% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Cue Biopharma, Inc. trading at a premium to the broader market with a P/E of -0.88. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $12.67, suggesting 3414.56% upside. Our AI forecast model points to short-term weakness (-25.1% over two weeks), a medium-term fall (-8.46% over three months), and a longer-term gain (210.68% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Cue Biopharma, Inc. (CUE) stock price?

Cue Biopharma, Inc. (NASDAQ: CUE) stock price is $0.36 in the last trading session. During the trading session, CUE stock reached the peak price of $0.40 while $0.34 was the lowest point it dropped to. The percentage change in CUE stock occurred in the recent session was -8.25% while the dollar amount for the price change in CUE stock was - $0.03.

CUE's industry and sector of operation?

The NASDAQ listed CUE is part of Biotechnology industry that operates in the broader Healthcare sector. Cue Biopharma, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of CUE?

Dr. Ronald D. Seidel III, Ph.D.
Co-Founder
Dr. Anish Suri Ph.D.
Pres & Chief Scientific Officer
Dr. Matteo Levisetti M.D.
Chief Medical Officer
Mr. Daniel R. Passeri J.D., M.Sc., MSc.
Chief Executive Officer & Director
Ms. Kerri-Ann Millar
Chief Financial Officer
George B. Zavoico Ph.D.
Vice President of Investor Relations & Corporation Devel.
Mr. Colin G. Sandercock J.D., MSE
Senior Vice President, Gen. Counsel & Sec.
Dr. Kenneth J. Pienta M.D.
Acting Chief Medical Officer
Dr. Steven C. Almo
Co-Founder and Chairman of Scientific & Clinical Advisory Board
Dr. Rodolfo J. Chaparro
Co-Founder & Senior Advisor
Ms. Patricia Nasshorn
Chief Bus. Officer

How CUE did perform over past 52-week?

CUE's closing price is 56.74% higher than its 52-week low of $0.23 where as its distance from 52-week high of $1.54 is -76.59%.

How many employees does CUE have?

Number of CUE employees currently stands at 41.

Link for CUE official website?

Official Website of CUE is: https://www.cuebiopharma.com

How do I contact CUE?

CUE could be contacted at phone 617 949 2680 and can also be accessed through its website. CUE operates from 21 Erie Street, Boston, MA 02139, United States.

How many shares of CUE are traded daily?

CUE stock volume for the day was 979.28K shares. The average number of CUE shares traded daily for last 3 months was 832.47K.

What is the market cap of CUE currently?

The market value of CUE currently stands at $28.42M with its latest stock price at $0.36 and 78.84M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	41
Beta	1.47
Sales or Revenue	$5.49M
5Y Sales Change%	1.114%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

CUE Company Profile and Key Details

Cue Biopharma

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Company Overview

Technical Performance

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Valuation Metrics

Price Forecast & Outlook

Key Takeaways